| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.6 |
| mRNA | CID-5951923 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.6 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | 0.09 | 0.6 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.6 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | AG-014699 | GDSC1000 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | XMD13-2 | GDSC1000 | pan-cancer | AAC | -0.016 | 0.6 |